Integral Diagnostics Ltd (ASX: IDX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Integral Diagnostics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $882.66 million
P/E Ratio 93.09
Dividend Yield 2.53%
Shares Outstanding 372.43 million
Earnings per share 0.025
Dividend per share 0.06
Year To Date Return -20.45%
Earnings Yield 1.07%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Integral Diagnostics Ltd (ASX: IDX)
    Latest News

    blockletters spelling dividends bank yield
    Dividend Investing

    2 growing ASX dividend shares for income investors

    Rural Funds Group (ASX:RFF) and this excellent ASX dividend share could be quality options for income investors. Here's why...

    Read more »

    Dividend Investing

    2 ASX shares that could be dividend stars of the future

    Kogan.com Ltd (ASX:KGN) and this ASX share could be dividend stars of the future...

    Read more »

    two hands wearing medical gloves make the shape of a heart, indicating the best healthcare shares on the ASX market
    Healthcare Shares

    The ASX healthcare shares Goldman Sachs rates as a buy

    Here are the ASX healthcare shares rated as buys from Goldman Sachs' 4th small/mid-cap healthcare forum this week.

    Read more »

    A man stands with arms crossed in front of a giant shadow of a body builder representing ASX small-cap stocks.
    Small Cap Shares

    2 small cap ASX dividend shares to buy

    Integral Diagnostics Ltd (ASX:IDX) and this small cap ASX dividend share could be great long term options for income investors...

    Read more »

    IAG share price broker upgrade buy
    Dividend Investing

    Top broker names 2 ASX dividend shares to buy

    Coles Group Ltd (ASX:COL) and this ASX dividend share are rated as buys by a leading broker. Here's what you need…

    Read more »

    ⏸️ ASX Shares

    Top broker tips Integral Diagnostics (ASX:IDX) share price to climb 22% from here

    Here's why the Integral Diagnostics Ltd (ASX:IDX) share price could be going 22% higher from where it trades today...

    Read more »

    ASX dividend shares represented by cash in jeans back pocket
    ⏸️ Income

    2 highly rated ASX dividend shares to buy now

    Wesfarmers Ltd (ASX:WES) and this buy-rated ASX dividend share could be great options for income investors right now. Here's why...

    Read more »

    Share Market News

    Integral Diagnostics (ASX:IDX) share price lifts on strong half-year results

    The Integral Diagnostics share price is up today after the company reported strong half-year results. Here's a closer look.

    Read more »

    Share Market News

    Integral Diagnostics share price on watch following FY 2020 earnings release

    The Integral Diagnostics Ltd (ASX: IDX) share price is on watch this morning following the release of its full year…

    Read more »

    Share Market News

    ASX small-cap sector rallies strongly during April

    The Australian small-cap sector performed particularly strongly during April. Here we examine what was behind this strong market rally.

    Read more »

    a woman
    Share Gainers

    The ASX small cap stocks enjoying a Bill Shorten boost

    A select group of medical stocks are defying the S&P/ASX 200 (Index:^AXJO) (ASX:XJO) sell-off as they received a boost from…

    Read more »

    a woman
    Share Market News

    WAM Microcap Limited (ASX:WMI) declares special dividend, creates 31% returns

    WAM Microcap Limited (ASX:WMI) has reported its result for 30 June 2018.

    Read more »

    Frequently Asked Questions

    Yes, Integral Diagnostics historically pays two fully franked dividends a year.

    Integral Diagnostics generally pays its shareholder dividends in April and October.

    Integral Diagnostics Ltd listed on the ASX on 21 October 2015.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    06 Mar 2025 $0.0250 100.00% Interim 07 Apr 2025
    30 Aug 2024 $0.0330 100.00% Final 03 Oct 2024
    29 Feb 2024 $0.0250 100.00% Interim 02 Apr 2024
    31 Aug 2023 $0.0350 100.00% Final 04 Oct 2023
    02 Mar 2023 $0.0250 100.00% Interim 04 Apr 2023
    01 Sep 2022 $0.0300 100.00% Final 05 Oct 2022
    01 Mar 2022 $0.0400 100.00% Interim 04 Apr 2022
    02 Sep 2021 $0.0700 100.00% Final 06 Oct 2021
    01 Mar 2021 $0.0550 100.00% Interim 06 Apr 2021
    28 Aug 2020 $0.0400 100.00% Final 01 Oct 2020
    28 Feb 2020 $0.0550 100.00% Interim 07 Apr 2020
    30 Aug 2019 $0.0500 100.00% Final 02 Oct 2019
    01 Mar 2019 $0.0500 100.00% Interim 02 Apr 2019
    31 Aug 2018 $0.0400 100.00% Final 04 Oct 2018
    31 Jan 2018 $0.0400 100.00% Interim 05 Mar 2018
    31 Aug 2017 $0.0000 100.00% Final 04 Oct 2017
    28 Feb 2017 $0.0300 100.00% Interim 30 Mar 2017
    31 Aug 2016 $0.0400 100.00% Final 04 Oct 2016

    IDX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Integral Diagnostics Ltd

    Integral Diagnostics Ltd (ASX: IDX) is an Australian healthcare services company providing medical imaging services. 

    The group operates in a single business providing diagnostic imaging to general practitioners, medical specialists, and allied health professionals and their patients. 

    The company operates more than 90 radiology clinics across Australia and New Zealand. It is also a joint venture partner in Medx, expanding its services to the United Kingdom and Ireland.

    IDX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    28 Apr 2025 $2.29 $0.02 0.88% 1,089,701 $2.29 $2.34 $2.27
    24 Apr 2025 $2.27 $0.02 0.89% 733,790 $2.27 $2.30 $2.26
    23 Apr 2025 $2.25 $0.02 0.90% 1,657,830 $2.23 $2.27 $2.20
    22 Apr 2025 $2.23 $-0.02 -0.89% 342,096 $2.27 $2.27 $2.19
    17 Apr 2025 $2.25 $-0.06 -2.60% 1,001,165 $2.32 $2.32 $2.23
    16 Apr 2025 $2.31 $0.06 2.67% 507,043 $2.25 $2.32 $2.25
    15 Apr 2025 $2.25 $0.02 0.90% 1,361,185 $2.21 $2.26 $2.18
    14 Apr 2025 $2.23 $-0.03 -1.33% 969,232 $2.28 $2.28 $2.21
    11 Apr 2025 $2.26 $-0.01 -0.44% 3,713,327 $2.28 $2.28 $2.18
    10 Apr 2025 $2.27 $0.14 6.57% 1,086,386 $2.28 $2.30 $2.23
    09 Apr 2025 $2.13 $-0.04 -1.84% 1,200,270 $2.17 $2.19 $2.11
    08 Apr 2025 $2.17 $0.03 1.40% 968,101 $2.15 $2.20 $2.14
    07 Apr 2025 $2.14 $-0.14 -6.14% 1,991,798 $2.25 $2.25 $2.12
    04 Apr 2025 $2.28 $0.03 1.33% 660,307 $2.21 $2.29 $2.21
    03 Apr 2025 $2.25 $-0.02 -0.88% 475,738 $2.29 $2.29 $2.21
    02 Apr 2025 $2.27 $0.00 0.00% 400,083 $2.25 $2.29 $2.24
    01 Apr 2025 $2.27 $-0.02 -0.87% 1,701,803 $2.29 $2.31 $2.19

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    07 Apr 2025 James Hall Issued 2,088 $4,738
    Dividend Reinvestment Plan (DRP).
    11 Mar 2025 Raelene Murphy Buy 15,000 $35,400
    On-market trade.
    05 Mar 2025 Ian Kadish Buy 25,000 $53,950
    On-market trade.
    04 Mar 2025 James Hall Buy 36,000 $78,840
    On-market trade.
    07 Nov 2024 James Hall Buy 1,833 $5,425
    On-market trade.
    01 Nov 2024 Ian Kadish Issued 327,566 $979,422
    Issue of securities. 1,004,570 Rights
    16 Sep 2024 Ian Kadish Issued 29,072 $74,424
    Issue of securities. 677,004 Rights
    30 Aug 2024 Ian Kadish Exercise 26,035 $67,691
    Conversion of securities. 647,932 Rights,
    30 Aug 2024 Ian Kadish Issued 26,035 $67,691
    Conversion of securities.
    27 Aug 2024 Ian Kadish Expiry 184,616 $480,001
    As advised by the company. Lapsed, 673,967 Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Andrew James Fay Non-Executive Director Jul 2022
    Mr Fay brings to the Board over 30 years of experience in funds and investment management, including Chief Executive Officer and Chief Investment Officer roles at Deutsche Asset Management Limited. He also held several other senior investment roles at Deutsche Asset Management and previously at AMP Capital. From 1998 to 2006, he was a member of the Investment Board Committee of the Financial Services Council. Andrew is an experienced company director across ASX listed, private and regulated entities and accordingly brings to the Board skills in financial and risk management, capital markets, executive remuneration frameworks, strategy, investment, and corporate governance. He is also Chair of the People and Culture Committee.
    Ms Raelene Margaret Murphy Non-Executive Director Oct 2017
    Ms Murphy has over 30 years of experience in strategic, financial, and operational leadership in both industry and professional advisory, after beginning her career in audit. She was formerly a Partner in a national accounting firm, Managing Director of Korda Mentha and CEO of the Delta Group. In her professional advisory career, she specialized in operational and financial restructuring, with a particular emphasis on merger and acquisition integration across a range of public and private companies. Raelene is a Fellow of Chartered Accountants Australia and New Zealand and has extensive experience as Chair of Audit and Risk Committees for ASX listed companies. She is Member of the Risk, Compliance and Sustainability Committee and a Member of the People and Culture Committee.
    Ms Ingrid Anne Player Non-Executive Director Aug 2023
    Ms Player has more than 20 years of experience in the healthcare industry, gained from leadership roles across the private, public and not for profit sectors. In her executive career, Ms Player was Group Executive Legal, Governance and Sustainability at Healthscope, one of Australia's largest private healthcare providers. As a qualified lawyer, she previously worked in private legal practice in Australia and Europe specializing in corporate law, M&A and capital markets. She brings to the Board experience in leveraging corporate transactions and major capital projects to achieve strategic outcomes, as well as skills in risk management, government relations, sustainability and corporate governance. She is Chair of the Risk, Compliance and Sustainability Committee and a Member of the People and Culture Committee.
    Mr James Tobias Hall Non-Executive DirectorNon-Executive Chairman Sep 2023
    Mr Hall has experience in Australia and New Zealand and is an experienced Board and Committee Chair. Mr Hall was Group CEO of St Vincents Health Australia from 2014 to 2022, He has also overseen multisite, for-profit generating businesses at both board and executive levels in employment services, early learning services and aged care. His experience in M&A includes the acquisition of ABC Childcare from administration. Mr Hall is currently non-executive Chair of Sana Health Group, non-executive Chair of For Purpose Aged Care, non-executive Director of UNICEF Australia, a trustee of Yajilarra and advisory board member for Fujitsu Australia and New Zealand. He is a Member of the Risk, Compliance and Sustainability Committee and a Member of the People and Culture Committee.
    Dr Ian Kadish Chief Executive OfficerManaging Director May 2017
    Mr Kadish began his career as a medical doctor in Johannesburg, South Africa. Ian was helpful in growing the group from five hospitals with a market capitalisation of $60m, to 119 hospitals and a market capitalisation of $3bn. Since migrating to Australia in 2006, Dr Kadish's roles have included CEO and MD of Healthcare Australia, CEO and MD of Pulse Health Group and CEO of Laverty Pathology. He is also a Director of the Australian Diagnostic Imaging Association (ADIA). He is also Member of the Integral Clinical Leadership Committee. He is a Member of the Integral Clinical Leadership Committee.
    Ms Laura Nicole McBain Non-Executive Director Dec 2024
    Ms McBain has executive and leadership experience having held roles as Managing Director at Bellamys Australia, Maggie Beer Holdings and Lark Distilling.
    Dr Kevin (Kai-Chung) Shaw Non-Executive Director Dec 2024
    Dr Shaw is the Director of Medical Imaging at University Hospital Geelong.
    Mr Manish Mittal Non-Executive Director Feb 2025
    --
    Mr John J Merity Company Secretary Jun 2024
    -
    Craig White Chief Financial Officer
    -
    John J Merity Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Limited 42,793,666 18.29%
    J P Morgan Nominees Australia Pty Limited 39,158,798 16.74%
    HSBC Custody Nominees (Australia) Limited 38,626,662 16.51%
    HSBC Custody Nominees (Australia) Limited A/C 2 4,678,603 2.00%
    Warbont Nominees Pty Ltd (Unpaid Entrepot A/c) 4,119,561 1.76%
    Washington H Soul Pattinson And Company Limited 4,087,223 1.75%
    HSBC Custody Nominees (Australia) Limited (NT COMNWLTH Super Corp A/C) 3,906,185 1.67%
    Citicorp Nominees Pty Limited (Colonial First State Inv A/C) 3,552,881 1.52%
    BNP Paribas Nominees Pty Ltd (Hub24 Custodial Serv Ltd) 3,407,901 1.46%
    New Imaging Pty Ltd (New Imaging A/c) 3,389,045 1.45%
    Lethean Holdings Pty Ltd (Howitt No 8 A/c) 2,944,760 1.26%
    Firbar Pty Ltd (The Howitt No 4 A/c) 2,357,230 1.01%
    J A Mullins Pty Ltd (James A Mullins Family A/c) 2,316,051 0.99%
    Masfen Securities Limited 2,250,000 0.96%
    Mittal Holdings Pty Ltd (Howitt No 12 A/c) 2,085,907 0.89%
    Mr Vincent Michael O'Sullivan (O'Sullivan A/c) 2,020,000 0.86%
    Wyndham Salter Pty Ltd (The Howitt No 10 A/c) 1,792,947 0.77%
    A & S French Pty Ltd (The AJ French Family A/c) 1,778,327 0.76%
    BNP Paribas Nominees Pty Ltd (Agency Lending A/C) 1,711,682 0.72%
    BNP Paribas Noms Pty Ltd 1,636,566 0.70%

    Profile

    since

    Note